• Explore /
  • Poster
  • / Preliminary results from a phase I expansion study of ZG005, a bispecific antibody targeting TIGIT and PD-1, as monotherapy in patients with advanced solid tumors.

Preliminary results from a phase I expansion study of ZG005, a bispecific antibody targeting TIGIT and PD-1, as monotherapy in patients with advanced solid tumors.

Abstract Poster

Authors

null

Shukui Qin

Cancer Center of Jinling Hospital, Nanjing Chinese Medicine University, Nanjing, China

Shukui Qin , Ying Cheng , Qiming Wang , Shuxia Cheng , Xiaoli Chai , Lihua Wu , Yan Yu , Jianhua Shi , Xiumin Li , Lianlian Fan , Jin Xia , Yisheng Huang , Yinghua Ji , Zhixiang Zhuang , Lei Yang , Ou Jiang , Qinhong Zheng , Sihai Liao , Shanyong Yi , Huangyang Ye

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

PD1/PD-L1 Inhibitor Combinations

Clinical Trial Registration Number

CTR20220021

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr 2611)

DOI

10.1200/JCO.2024.42.16_suppl.2611

Abstract #

2611

Poster Bd #

90

Abstract Disclosures

Similar Posters

First Author: John Ebben

First Author: Jianqing Zhu

First Author: Miaozhen Qiu

First Author: Qin Xu